

RESOURCES

PEOPLE

AutoImmune Inc. (Lexington, MA) president and CEO **Robert C. Bishop** has been elected chairman of the company's board. He succeeds Barry Weinberg, who will remain on the board. AutoImmune also announced that it has promoted **Jo Ann Wallace** to senior vice president. Ms. Wallace joined the company in 1994 as vice president, corporate development.

Ribozyme Pharmaceuticals (Boulder, CO) has appointed **J. Wayne Cowens** vice president of clinical and regulatory affairs. Dr. Cowens most recently served as a division vice president of product development for Chiron Technologies.

John B. Douglas III has been named general counsel at Millennium Pharmaceuticals (Cambridge, MA). Most recently, he was a partner with the Boston law firm of Hutchins, Wheeler & Dittmar. In addition, Millennium has announced the appointment of **Kim Rubin** as associate general counsel, responsible for transactions. She was previously a partner with the Boston law firm of Hale and Dorr.

Vical (San Diego, CA) has appointed **R. Gordon Douglas, Jr.** to its board of directors. Dr. Douglas retired in April from Merck & Co., where he had been president of Merck Vaccines since 1991.

Michael Gilman has been appointed research director of molecular biology at Biogen (Cambridge, MA). Dr. Gilman joins Biogen from ARIAD Pharmaceuticals, where he served as executive vice president and CSO. Biogen also named **Jennifer Jackson** director, regulatory affairs. Dr. Jackson was previously executive director, international regulatory affairs for Bristol-Myers Squibb.

Biovector Therapeutics (Toulouse, France) has announced the appointment of **Georges Hibon** to its board of directors. Mr. Hibon was the president of Pasteur Merieux Connaught of North America from 1990 to 1998, and remains a board member of that company.

Chiron (Emeryville, CA) has named president and chief executive **Sean Lance** to the additional post of board chairman. He replaces one of the company founders, William Rutter, who will continue on the board. In addition, chief scientific officer and president of R&D **Lewis T. "Rusty" Williams** has been named to the board of directors. He will serve for an initial two-year term, expiring in 2001.

Nelson L. Levy has been elected to the board of directors of Targeted Genetics (Seattle, WA). Dr. Levy is currently chairman and

CEO of CoreTechs Corp., a private healthcare and biotechnology consulting firm.

Molecumetics (Bellevue, WA) has appointed **Yat Sun Or** as vice president, medicinal chemistry. Previously, Dr. Or was senior project leader at Abbott Laboratories. Molecumetics has also announced the promotion of **Ed Field**, senior vice president and chief business officer, to president.

Oxagen Ltd. (Oxford, UK) has announced the appointments of **Roy Pettipher** as director of business development and **Gillian Waite** as head of clinical research. Dr. Pettipher joins the company from Pfizer, while Ms. Waite was previously senior manager of clinical operations at Amylin Pharmaceuticals.

Charles P. Rodi, previously director of Monsanto's genomic sequencing center, has been appointed vice president of molecular biology at Sequenom (San Diego, CA). Sequenom also announced that **Paul J. Heaney**, formerly senior director of new technology at Orchid Biocomputer, has been named vice president of advanced systems.

ImmunoGen (Norwood, MA) has announced the appointment of **Pauline Jen Ryan** as senior director of business development, a newly created position. Ms. Ryan was most recently vice president at Capital Management Consulting.

LifeCell Corp. (The Woodlands, TX) has elected president and CEO **Paul G. Thomas** to the post of chairman of the board. In addition, the company has named **Fenel M. Eloi** as senior vice president and CFO, **Patrick N. Bergstedt** as vice president, marketing and business development, and **Hugh Hansard** as vice president, information services and materials management. Previously, Mr. Eloi was senior vice president and CFO of Genome Therapeutics Corp., Mr. Bergstedt served as vice president of Centeon, and Mr. Hansard served in various management positions at Warner Lambert and Baxter Healthcare.

CpG ImmunoPharmaceuticals (Wellesley, MA) has appointed **Ralph R. Venhaus** to the newly created position of vice president, medical affairs. He most recently held the same position at ASTA Medica.

Nancy Wetherbee has been named vice president of business development at Phytera (Worcester, MA). Most recently, she was vice president of business development and strategic planning at Oncormed.